LivaNova PLC (NASDAQ:LIVN) Shares Acquired by Deutsche Bank AG

Deutsche Bank AG increased its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 49.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 48,905 shares of the company’s stock after purchasing an additional 16,227 shares during the quarter. Deutsche Bank AG owned 0.09% of LivaNova worth $2,265,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. raised its position in LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after buying an additional 219 shares during the last quarter. Sterling Capital Management LLC raised its holdings in LivaNova by 800.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after purchasing an additional 1,441 shares in the last quarter. Vestcor Inc purchased a new position in LivaNova during the fourth quarter worth about $204,000. Optimize Financial Inc acquired a new stake in LivaNova in the fourth quarter valued at about $208,000. Finally, Corton Capital Inc. purchased a new stake in LivaNova in the 4th quarter valued at approximately $214,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Stock Down 1.1%

LIVN opened at $43.18 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The company has a market cap of $2.35 billion, a price-to-earnings ratio of 102.81 and a beta of 0.84. LivaNova PLC has a one year low of $32.48 and a one year high of $61.94. The business’s fifty day moving average is $38.74 and its two-hundred day moving average is $44.71.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on LIVN shares. Barclays cut their target price on LivaNova from $56.00 to $55.00 and set an “equal weight” rating for the company in a research note on Thursday, May 8th. Stifel Nicolaus cut their price objective on LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Needham & Company LLC reissued a “buy” rating and issued a $64.00 target price on shares of LivaNova in a report on Tuesday, May 13th. Mizuho lowered their price target on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. Finally, Wolfe Research upgraded shares of LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 price objective for the company in a research note on Tuesday. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $59.29.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.